1
|
Chen Y, Li M, Cao J, Cai G, Li X, Liu Y, Chen W. CTLA-4 promotes lymphoma progression through tumor stem cell enrichment and immunosuppression. Open Life Sci 2021; 16:909-919. [PMID: 34553071 PMCID: PMC8422981 DOI: 10.1515/biol-2021-0094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Revised: 07/07/2021] [Accepted: 07/08/2021] [Indexed: 11/15/2022] Open
Abstract
The recurrence rate of lymphoma is very high, and tumor stem cells may be an important mechanism. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can inhibit antitumor immunity and promote cancer progression, but its role and mechanism in lymphoma are still unclear. Here we collected lymphoma tissue and peripheral blood from patients with diffuse large B-cell lymphoma (DLBCL). Results showed that CTLA-4 expression and CD44+ cell in the high-risk group were significantly higher than that in the low-risk group. Correlation analysis showed that CTLA-4 expression positively correlated with CD44+ cell in lymphoma tissue and regulatory T (Treg) cells in lymphocytes. In vitro experiment showed that CTLA-4 increased the ratio of lymphoma stem cells, and proliferation and invasion of lymphoma cells through TGF-β pathway. Moreover, CTLA-4 enhanced the proliferation of Treg cells induced by lymphoma cells. Animal experiments showed that CTLA-4 can promote transplanted lymphoma growth. Immunohistochemistry results showed that both Ki-67 and CD44+ cells increased significantly in the CTLA-4 group. TGF-β neutralization can significantly block these effects of CTLA-4. In conclusion, CTLA-4 promoted DLBCL progression through lymphoma stem cell enrichment and immunosuppression.
Collapse
Affiliation(s)
- Yan Chen
- Department of Integrated TCM and Western Medicine, Central Hospital of Yiyang City, Yiyang, Hunan, 413200, China
| | - Meng Li
- Department of Pathology, The 8th Medical Center, Chinese PLA General Hospital, Beijing 100091, China
| | - Jian Cao
- Department of Integrated TCM and Western Medicine, Central Hospital of Yiyang City, Yiyang, Hunan, 413200, China
| | - Guohong Cai
- Department of Integrated TCM and Western Medicine, Central Hospital of Yiyang City, Yiyang, Hunan, 413200, China
| | - Xiantao Li
- Department of Integrated TCM and Western Medicine, Central Hospital of Yiyang City, Yiyang, Hunan, 413200, China
| | - Yuejiao Liu
- Department of Pathology, The 8th Medical Center, Chinese PLA General Hospital, Beijing 100091, China
| | - Wen Chen
- Department of Pathology, The 8th Medical Center, Chinese PLA General Hospital, Beijing 100091, China
| |
Collapse
|
2
|
Zhao Q, Sun XY, Wu B, Shang Y, Huang X, Dong H, Liu H, Chen W, Gui R, Li J. Construction of biomimetic silver nanoparticles in the treatment of lymphoma. Mater Sci Eng C Mater Biol Appl 2020; 119:111648. [PMID: 33321684 DOI: 10.1016/j.msec.2020.111648] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/11/2020] [Revised: 10/10/2020] [Accepted: 10/13/2020] [Indexed: 02/06/2023]
Abstract
Lymphoma is a well-known malignant tumor in the human body. Although many anticancer drugs have been developed to improve the survival rate of patients, about 40% of patients continue to be recurrent or refractory, a key issue needing remedy. Therefore, it is necessary to identify alternative treatments to reduce the disease's mortality. To this effect, a new type of anti-lymphoma nanocomplex FA@RBCm-AgNPs was prepared using AgNPs as the core of nanoparticles along with the targeting molecule folic acid inserted erythrocyte membrane as the shell. The biomimetic properties of red blood cell membrane (RBCm) endow F-RAN with good biocompatibility as well as the ability to evade clearance of the reticuloendothelial system. In addition, F-RAN was modified with folic acid to actively and selectively identify tumor cells. In vivo and in vitro experiments demonstrate that F-RAN can inhibit lymphoma cells and induce apoptosis of stem cells while promoting apoptosis of lymphoma with no obvious side effects. Hence, F-RAN may serve as a new treatment for lymphoma.
Collapse
Affiliation(s)
- Qiangqiang Zhao
- Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha 410013, PR China; Department of Hematology, The Qinghai Provincial People's Hospital, Xining 810007, PR China
| | - Xiao Ying Sun
- Nursing School, Soochow University, Suzhou 215000, PR China; Department of Emergency, The Qinghai Provincial People's Hospital, Xining 810007, PR China
| | - Bin Wu
- Department of Transfusion Medicine, Wuhan Hospital of Traditional Chinese and Western Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, PR China
| | - Yinghui Shang
- Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha 410013, PR China
| | - Xueyuan Huang
- Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha 410013, PR China
| | - Hang Dong
- Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha 410013, PR China
| | - Haiting Liu
- Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha 410013, PR China
| | - Wansong Chen
- College of Chemistry and Chemical Engineering, Central South University, Changsha 410083, PR China
| | - Rong Gui
- Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha 410013, PR China.
| | - Jian Li
- Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha 410013, PR China.
| |
Collapse
|
3
|
Touil Y, Segaoula Z, Thuru X, Galiègue-Zouitina S, Tierny D, Quesnel B. Aggressiveness Potential of Spontaneous Canine Mucosal Melanoma Can Dictate Distinct Cancer Stem Cell Compartment Behaviors in Regard to Their Initial Size and Expansion Abilities. Stem Cells Dev 2020; 29:919-928. [PMID: 32423311 PMCID: PMC7374591 DOI: 10.1089/scd.2019.0223] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Mucosal melanoma represents one of the most highly metastatic and aggressive subtypes of melanoma. The biology of mucosal melanoma is poorly documented, and the lack of experimental models makes it difficult to design and test new therapies. Dogs are frequently affected by melanomas of the oral cavity, making spontaneous canine melanoma a potentially predictable model for their human counterpart. We recently established and characterized two new canine mucosal melanoma cell lines named OCR_OCMM1 and OCR_OCMM2. Here, we identified quiescent cancer stem cell (CSC) subpopulations in both canine cell lines that displayed similarities to human quiescent CSCs: canine melanoma CSCs had the ability to self-renew, produced nonstem cell (SC) progeny, and formed melanospheres that recapitulated the phenotypic profile of the parental tumor. These CSCs also formed melanoma in immunodeficient mice, and the inhibition of PI3K/AKT signaling expanded the CSC pool. A subset of non-CSCs transitioned to become CSCs. OCR_OCMM1 and OCR_OCMM2 displayed different CSC compartment behaviors in regard to their initial size and expansion abilities. Collectively, this study showed that the OCR_OCMM1 and OCR_OCMM2 canine melanoma cell lines are powerful cellular tools to study melanoma SCs, not only for mucosal but also for the more common human cutaneous melanoma.
Collapse
Affiliation(s)
- Yasmine Touil
- University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR 9020, UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France
| | - Zacharie Segaoula
- University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR 9020, UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.,OCR (Oncovet Clinical Research), SIRIC ONCOLille, Parc Eurasante, Loos, France
| | - Xavier Thuru
- University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR 9020, UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France
| | - Sylvie Galiègue-Zouitina
- University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR 9020, UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France
| | - Dominique Tierny
- OCR (Oncovet Clinical Research), SIRIC ONCOLille, Parc Eurasante, Loos, France.,Oncovet Cancer Centre, Villeneuve d'Ascq, France
| | - Bruno Quesnel
- University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR 9020, UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France
| |
Collapse
|